Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of Therapeutic and Adverse Effects of Leupromer (Iranian Formulated LHRH agonist) and Eligard in patients with Metastatic Prostate Cancer -

Next Previous
Trial Profile

Comparison of Therapeutic and Adverse Effects of Leupromer (Iranian Formulated LHRH agonist) and Eligard in patients with Metastatic Prostate Cancer -

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 16 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use

Most Recent Events

  • 05 May 2013 Recruitment complete, according to the Iranian Registry of Clinical Trials.
  • 25 Jan 2013 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top